Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone Injectable Suspension SAD Study in Schizophrenia
NCT03627195Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lurasidone in schizophrenia (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation at Day 61, Maximum Serum Concentration [Cmax] for Lurasidone at Day 61 and 1 more. Started Jun 2018; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03627195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627195.